Blog

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Blog

Day One Biopharmaceuticals announces a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib

Photo from Day One Biopharmaceuticals/LinkedIn

Jul 27, 2024, 22:01

Day One Biopharmaceuticals announces a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib

Day One Biopharmaceuticals shared a post on LinkedIn:

”We are pleased to announce a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib. This collaboration highlights our shared commitment to bring novel therapeutics to patients worldwide who have limited treatment options. Learn more.”

Source: Day One Biopharmaceuticals/LinkedIn

cancer cancer treatment Day One Biopharmaceuticals Ipsen OncoDaily Oncology tovorafenib

Aug 18, 2024, 01:43

Steven D Wexner: SEER database analysis of predictors of LN metastasis in neuroendocrone tumors

Aug 17, 2024, 08:58

Neha Mehta-Shah: Wonderful St. Louis tradition of the arts bringing together community!

Aug 17, 2024, 20:44

Palliative care is an added layer of support - Kidney CAN

Aug 17, 2024, 20:40

Register for HTTR24 - IASLC

Aug 17, 2024, 20:35

Nominate a colleague for a Fondazione Pezcoller - European Association for Cancer Research Award

Aug 17, 2024, 20:27

Andrea Carai: Our data suggest that VR is overall useful for pediatric neurosurgical oncology

Aug 17, 2024, 20:21

Dunkley’s will be lacing up their walking shoes for the Shine Night Walk in Bristol in support of Cancer Research UK - Dunkley's Chartered Accountants

Aug 17, 2024, 20:10

CANCaRe Africa's Voice of the families: Gashanew and his father

Aug 17, 2024, 20:07

Roche Africa CEO recently spoke of the care gap that exists throughout the African continent

Aug 17, 2024, 20:01

Miriam Mutebi: Cancer fatalism—the belief that cancer is incurable

Aug 17, 2024, 19:56

Oncotype DX Colon Recurrence Score in stage II colon cancer, summary by Erman Akkus

Aug 17, 2024, 19:53

First European Patient Dosed in Phase I Trial Of Novel CD30-Directed ADC FOR Lymphomas - The START Center for Cancer Research